Markwalter, Chester E. et al. published their research in Journal of Controlled Release in 2021 | CAS: 13590-42-6

(S)-Benzyl 2-(2,5-dioxooxazolidin-4-yl)acetate (cas: 13590-42-6) belongs to oxazolidine derivatives. Oxazolidines are well known as key portions of bioactive molecules or precursors of chiral molecules, as well as established chiral auxiliaries. Oxazolidines are cyclic condensation products of β-amino alcohols and aldehydes or ketone, and they undergo a facile and complete hydrolysis in aqueous solution. Alterations in carbonyl moiety control the rate of formation of a given β-amino alcohol.Recommanded Product: 13590-42-6

Sustained release of peptides and proteins from polymeric nanocarriers produced by inverse Flash NanoPrecipitation was written by Markwalter, Chester E.;Pagels, Robert F.;Hejazi, Ava N.;Ristroph, Kurt D.;Wang, Jiping;Chen, Ke;Li, Jian;Prud′homme, Robert K.. And the article was included in Journal of Controlled Release in 2021.Recommanded Product: 13590-42-6 This article mentions the following:

Peptide and protein therapeutics generally exhibit high potency and specificity and are increasingly important segments of the pharmaceutical market. However, their clin. applications are limited by rapid clearance and poor membrane permeability. Encapsulation of the peptide or protein into a nano-scale carrier can modify its pharmacokinetics and biodistribution. This might be employed to promote uptake in desired cell types or tissues, to limit systemic exposure, or to reduce the need for frequent injections. We have recently described inverse Flash NanoPptn. (iFNP), a scalable technique to encapsulate water-soluble therapeutics into polymeric nanocarriers, and have demonstrated improvements in therapeutic loading of an order of magnitude over comparable approaches. Here, we describe the formulation parameters that control release rates of encapsulated model therapeutics polymyxin B, lysozyme, and bovine serum albumin from nanocarriers produced using iFNP. Using a neutropenic lung infection mouse model with a multi-drug resistant Acinetobacter baumannii clin. isolate, we demonstrate enhanced therapeutic effect and safety profile afforded by nanocarrier-encapsulated polymyxin B following pulmonary administration. The encapsulated formulation reduced toxicity observed at elevated doses and resulted in up to 2.7-log10 reduction in bacterial burden below that of unencapsulated polymyxin B. These results establish the promise of iFNP as a platform for nanocarrier delivery of water-soluble therapeutics. In the experiment, the researchers used many compounds, for example, (S)-Benzyl 2-(2,5-dioxooxazolidin-4-yl)acetate (cas: 13590-42-6Recommanded Product: 13590-42-6).

(S)-Benzyl 2-(2,5-dioxooxazolidin-4-yl)acetate (cas: 13590-42-6) belongs to oxazolidine derivatives. Oxazolidines are well known as key portions of bioactive molecules or precursors of chiral molecules, as well as established chiral auxiliaries. Oxazolidines are cyclic condensation products of β-amino alcohols and aldehydes or ketone, and they undergo a facile and complete hydrolysis in aqueous solution. Alterations in carbonyl moiety control the rate of formation of a given β-amino alcohol.Recommanded Product: 13590-42-6

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem